← Eichor
Condition: Advanced Neuroendocrine Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Neuroendocrine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230BostonGene and Exigent Genomic INsight Study
Phase N/A · 7 location(s) · BostonGene · NCT06272864Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Phase 1 · 3 location(s) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · NCT06424665A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus C
Phase 3 · 165 location(s) · Boehringer Ingelheim · NCT07544654A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06936735A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Ot
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06505824A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/Phase 2 · 6 location(s) · Simcha IL-18, Inc. · NCT04787042Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Phase 1/Phase 2 · 25 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT06157827Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Phase 1 · 2 location(s) · Brigham and Women's Hospital · NCT06062745Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06283719A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.